QQ客服 官方微博 反馈留言

	Efficacy, immunogenicity and safety of the AS04-HPV-16/18 vaccine in Chinese women aged 18-25 years: End-of-study results from a phase II/III, randomised, controlled trial
	Zhu Feng-Cai; Hu Shang-Ying; Hong Ying; Hu Yue-Mei; Zhang Xun; Zhang Yi-Ju; Pan Qin-Jing; Zhang Wen-Hua; Zhao Fang-Hui; Zhang Cheng-Fu
	2019
关键词	AS04-HPV-16/18 vaccine China efficacy human papillomavirus immunogenicity safety
ISSN号	2045-7634
DOI	10.1002/cam4.2399
URL标识	查看原文
收录类别	PUBMED
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/6338732
专题	中国医学科学院 北京协和医学院
推荐引用方式 GB/T 7714	Zhu Feng-Cai,Hu Shang-Ying,Hong Ying,et al. Efficacy, immunogenicity and safety of the AS04-HPV-16/18 vaccine in Chinese women aged 18-25 years: End-of-study results from a phase II/III, randomised, controlled trial[J],2019.
APA	Zhu Feng-Cai.,Hu Shang-Ying.,Hong Ying.,Hu Yue-Mei.,Zhang Xun.,...&Struyf Frank.(2019).Efficacy, immunogenicity and safety of the AS04-HPV-16/18 vaccine in Chinese women aged 18-25 years: End-of-study results from a phase II/III, randomised, controlled trial..
MLA	Zhu Feng-Cai,et al."Efficacy, immunogenicity and safety of the AS04-HPV-16/18 vaccine in Chinese women aged 18-25 years: End-of-study results from a phase II/III, randomised, controlled trial".(2019).

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。